Jukka T Salonen
Finland
Jukka is the CEO for MAS - Metabolic Analytical Services Oy. He has extensive experience in the International Life Science industry as well as an earlier prolific background in academic research. He has a broad specialist knowledge of the sector, covering all key elements of Biotech, Pharmaceuticals and Diagnostics. He has played a focal role in attaining a licensing deal with Eli Lilly, including licencing to Eli Lilly Inc drug targets in high density hypolipoproteinemia. The deal totalled tens of millions of Euros. He is responsible for In-silico compound design and drug discovery.